LYCOS RETRIEVER 
Melanoma: Melanoma Research
built 640 days ago
Melanoma is a leading cause of new cancer diagnoses. More effective options for prevention, diagnosis, and treatment are therefore urgently needed. From a basic and clinical research perspective, melanoma occupies the crossroads of molecular biology and immunology. An externally visible tumor, it offers a unique opportunity to query lesions at the earliest stages of carcinogenesis for molecular events or signatures portending progression, invasion, and dissemination. And, as one of the most highly immunogenic human neoplasms, it provides an ideal context for understanding interactions between the human immune system and cancer. Despite emerging knowledge about the basic immunology and molecular biology of cancer, these new insights have yet to translate into significant clinical benefits for patients with melanoma.
Source:
The Society for Melanoma Research (SMR) is an all-volunteer group of scientists working to find the mechanisms responsible for melanoma and, consequently, new therapies for this cancer. SMR contributes to advances in melanoma research by bringing together researchers in a non-competitive way to unite the scientific community. The Society has commissioned the Roadmap for Melanoma which outlines the key targets for research and therapy that need to be addressed by 2010. www.melanomacongress07.net
Source:
The Marit Peterson Fund for Melanoma Research supports research under the direction of Jeffrey E. Lee, M.D., professor of surgical oncology in the Melanoma and Skin Center at M. D. Anderson. Dr. Lee and his research team are investigating the inherited genome for melanoma in a study expected to require $500,000 in funding over four years.
Source:
The Society for Melanoma Research meeting ... marks a change in the Society's main scientific publication. Pigment Cell Research will become Pigment Cell and Melanoma Research to underscore the rapidly expanding potential in melanoma research, and will serve as a focal point for the international research community in discussing advances in field. A preview issue produced for the Congress will be dedicated to melanoma research. The renamed journal will be officially launched in January 2008.
Source:
Melanoma is the most malignant of all the skin cancers and therefore has the poorest prognosis. If found in the mouth, the prognosis is even more grim. Approximately 25% of dogs diagnosed with oral melanoma will survive for one year; 75% will not survive even this long. The future does hold promise that genetic therapies directed at stimulating the dog's own immune system to attack and destroy tumor cells may be developed. There is presently research in this area.
Source:
MORE ABOUT
Melanoma Research